Cardinal Health, Inc. CAH
Composite 57/100; the shares have moved about 25% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 39/100 — a slight mark against it.
Momentum ranks 78/100 — a strong point in its favour. Growth ranks 69/100 — a moderate point in its favour. Valuation ranks 58/100 — a slight point in its favour.
Quality ranks 39/100 — a slight mark against it.
What the company does Cardinal Health, Inc. (CAH) distributes branded and generic pharmaceuticals, specialty products, and medical/surgical supplies to hospitals, pharmacies, and clinical labs. It also repackages generics, operates specialty-pharmacy services, and sells Cardinal Health–branded medical devices.
Key financials Gross margin 3.8%, operating margin 1.3%, net margin 0.7%. ROE 0.0%, ROA 3.7%, ROCE 18.8%. Revenue grew 14.2% and EPS 11.0%. Debt/Equity –3.45, net debt/EBITDA 1.21, interest coverage 7.25, current ratio 0.88.
Stock health Sideravia overall score 59.8 (average quality, fairly valued, positive momentum). Growth 69.5, Momentum 75.3, Strength 65.7. Piotroski F-Score 7/9, Altman Z 5.05. Dividend yield 0.9%, payout 18.2%.
Price vs fair value The stock trades at a discount of 13.20% versus the analyst mean target of 270.94. - Recent global bond selloff weighed on stocks (2026-09-01) - Stocks retreated as global bond yields surged (2026-09-01) - Silchester’s EGM demand letter on Medipal may have heightened sector scrutiny (2026-09-02)
Looking forward Forward P/E 19.08 and PEG 0.27 suggest improved earnings visibility. EV/EBITDA 16.86 and FCF yield 8.5% indicate reasonable cash generation relative to enterprise value.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.